AIM
SAGE

Aigen Investment Management’s Sage Therapeutics SAGE Stock Holding History

Aigen Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,159
Closed -$128K – 1032
2025
Q1 		$128K Buy
+16,159
New +$118K 0.02% 669
2022
Q3 		– Sell
-12,524
Closed -$405K – 734
2022
Q2 		$405K Buy
+12,524
New +$420K 0.07% 343
2021
Q1 		– Sell
-7,475
Closed -$647K – 850
2020
Q4 		$647K Buy
+7,475
New +$551K 0.08% 308

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aigen Investment Management's SAGE Position: Q2 2025 in Review

Aigen Investment Management sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 16,159 shares — an estimated $128K sold.

Aigen Investment Management first reported a position in SAGE in Q4 2020 and held it in 3 quarters. The position peaked at $647K in Q4 2020. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Aigen Investment Management reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aigen Investment Management sold 16,159 Sage Therapeutics shares in Q2 2025, an estimated $128K.
  • Aigen Investment Management first reported a position in Sage Therapeutics in Q4 2020 and held it in 3 quarters.
  • Aigen Investment Management's Sage Therapeutics position peaked at $647K in Q4 2020.
  • 191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Aigen Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.